232 related articles for article (PubMed ID: 32666476)
1. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance.
Maity S; Pai KSR; Nayak Y
Pharmacol Rep; 2020 Aug; 72(4):799-813. PubMed ID: 32666476
[TBL] [Abstract][Full Text] [Related]
2. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
3. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
4. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
5. Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Wan S; Yan R; Jiang Y; Li Z; Zhang J; Wu X
J Biomol Struct Dyn; 2019 Oct; 37(16):4384-4394. PubMed ID: 30499387
[TBL] [Abstract][Full Text] [Related]
6. Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma.
Tripathi SK; Biswal BK
Drug Discov Today; 2021 Jun; 26(6):1466-1472. PubMed ID: 33581322
[TBL] [Abstract][Full Text] [Related]
7. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
9.
Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
[TBL] [Abstract][Full Text] [Related]
10. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
11. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
Takeda M; Nakagawa K
Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
13. Recent advances of novel targeted therapy in non-small cell lung cancer.
Katzel JA; Fanucchi MP; Li Z
J Hematol Oncol; 2009 Jan; 2():2. PubMed ID: 19159467
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
Wang S; Song Y; Yan F; Liu D
Front Med; 2016 Dec; 10(4):383-388. PubMed ID: 27770386
[TBL] [Abstract][Full Text] [Related]
15. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
16. Targeting EGFR in Lung Cancer: Current Standards and Developments.
Díaz-Serrano A; Gella P; Jiménez E; Zugazagoitia J; Paz-Ares Rodríguez L
Drugs; 2018 Jun; 78(9):893-911. PubMed ID: 29915896
[TBL] [Abstract][Full Text] [Related]
17. An Anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells.
Si Y; Pei X; Wang X; Han Q; Xu C; Zhang B
Protein Pept Lett; 2021; 28(11):1290-1297. PubMed ID: 34602035
[TBL] [Abstract][Full Text] [Related]
18. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
19. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
20. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
